THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-30461 | Medical Devices
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Therapies for Resistant and Recurrent Metastatic Cancer Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET
7.1 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Miraca Holdings
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Proteome Sciences
16.3 Boreal Genomics
16.4 Oxford Gene Technology
16.5 Illumina
16.6 Neogenomics Laboratories
16.7 Biotheranostics
16.8 Nanostring Technologies
16.9 Genomic Health
16.10 Thermo Fisher Scientific
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market by Type :Breast Cancer
Endocrine Cancer
Leukemia
Lymphoma
Bladder
Colorectal
Kidney
Ovary
Pancreas
Others
Market by Application :
Chemotherapy
Hormone Therapy
Biotherapy
Radiation Therapy
Surgery
Others
Companies
Miraca Holdings
Proteome Sciences
Boreal Genomics
Oxford Gene Technology
Illumina
Neogenomics Laboratories
Biotheranostics
Nanostring Technologies
Genomic Health
Thermo Fisher Scientific
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.